Shapiro Speaks to HBW Insight on P&G’s Supplement Co-Packaging

November 10, 2021 | Compliance Investigations & White Collar

Steven Shapiro was interviewed by HBW Insight for the article, “P&G Wraps Launch Of Super C Supplement Brand In Co-Packaging With DayQuil And NyQuil OTCs.

The story describes how Procter & Gamble may have exploited an ambiguity in the Food & Drug Administration’s policy when packaging its Super C supplement brand with DayQuil and Nyquil. The FDA, in a 2015 proposed rule, questioned the safety of packaging a supplement with a drug.

Steven noted that in the 2015 proposed rule, the FDA includes this explanation for its reservations about co-packaging a drug with a vitamin, mineral or supplement product: “In the case of a dietary supplement co-packaged with a drug, the co-packaging implies that the dietary supplement is intended to be used for a therapeutic purpose.”

Share this article:

Related News

Get legal updates and news delivered to your inbox